Regeneron is buying 23andMe out of bankruptcy for $256 million

fortune.com/article/regeneron-23andme-bankruptcy-256-million

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
In March 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved…

This story appeared on fortune.com, 2025-05-19 14:20:44.
The Entire Business World on a Single Page. Free to Use →